The London-listed drugmaker plans to buy all outstanding equity of TeneoTwo for upfront payment of $100 million on deal close.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Sherry Jacob-Phillips)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,416 GBX | -0.10% |
|
+0.32% | +17.13% |
05:25pm | Global markets live: Shell, UBS, Boeing, Berkshire Hathaway, Exxon... | ![]() |
01:20pm | ASTRAZENECA : Goldman Sachs maintains a Buy rating | ZD |
(Reuters) - AstraZeneca said on Tuesday it will acquire oncology firm TeneoTwo Inc in a deal worth up to $1.27 billion, including the company's initial stage T-cell engager.
The London-listed drugmaker plans to buy all outstanding equity of TeneoTwo for upfront payment of $100 million on deal close.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Sherry Jacob-Phillips)
1st Jan change | Capi. | |
---|---|---|
+17.13% | 244B | |
+52.58% | 797B | |
+40.55% | 628B | |
-7.08% | 351B | |
+17.50% | 323B | |
+10.73% | 300B | |
+1.39% | 223B | |
+6.27% | 163B | |
-4.95% | 153B | |
-1.39% | 118B |